Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
iTeos Therapeutics
Biotech
GSK on anti-TIGIT strategy: It’s 'not always about being first'
Months after Roche's second anti-TIGIT defeat, GSK is forging ahead with its own plans, including combining its TIGIT inhibitor with two other meds.
Max Bayer
Sep 9, 2022 10:40am
Roche's trial flop casts shadow on Big Pharma's $6B TIGIT bet
May 16, 2022 9:45am
Roche's TIGIT flop prompts GSK to evaluate next steps for rival
May 13, 2022 4:52am
GSK pays iTeos $625M upfront for rights to anticancer TIGIT drug
Jun 14, 2021 7:00am
Annexon, Inozyme, iTeos snag $564M in upsized IPOs
Jul 24, 2020 11:37am
iTeos reels in $125M to shepherd I-O prospects through clinic
Apr 1, 2020 2:32pm